Related Experiment Video
Updated: Jul 17, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma
Maria Lapuente1, Dawn Conway2, Laura S Wood3
1St. Bartholomew's Hospital.
Background:
The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.
Objectives:
This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.
Methods:
This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.
Findings:
Oncology nurses can provide comprehensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct administration, and promptly recognizing and managing immune-related adverse events.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Urinary Tract Calculi III: Medical Management
Targeted Cancer Therapies
There are several types of targeted therapies against...

